ProCE Banner Activity

CAR T-Cell Therapy in Lymphomas and Acute Lymphoblastic Leukemia: Exciting Data From ASH 2018

Clinical Thought
At ASH 2018, we saw important updates to registration trials and “real-world” data on CAR T-cell therapies. Here’s my take on how we should be integrating these products into patient care.

Released: April 29, 2019

Expiration: April 27, 2020

Share

Faculty

Daniel J. DeAngelo

Daniel J. DeAngelo, MD, PhD

Professor of Medicine
Harvard Medical School
Chief, Division of Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology

Faculty Disclosure

Primary Author

Daniel J. DeAngelo, MD, PhD

Professor of Medicine
Harvard Medical School
Chief, Division of Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts

Daniel J. DeAngelo, MD, PhD, has disclosed that he has received consulting fees from Amgen, Blueprint, Celgene, Incyte, Jazz, Novartis, Pfizer, Shire, and Takeda and funds for research support from AbbVie, Blueprint, Glycomimetics, and Novartis.